DNAM-1-based  ||| S:0 E:13 ||| FW
chimeric  ||| S:13 E:22 ||| FW
antigen  ||| S:22 E:30 ||| FW
receptors  ||| S:30 E:40 ||| FW
enhance  ||| S:40 E:48 ||| FW
T  ||| S:48 E:50 ||| FW
cell  ||| S:50 E:55 ||| FW
effector  ||| S:55 E:64 ||| FW
function  ||| S:64 E:73 ||| FW
and  ||| S:73 E:77 ||| CC
exhibit  ||| S:77 E:85 ||| NN
in  ||| S:85 E:88 ||| IN
vivo  ||| S:88 E:93 ||| JJ
efficacy  ||| S:93 E:102 ||| NN
against  ||| S:102 E:110 ||| IN
melanoma  ||| S:110 E:119 ||| FW
Chimeric  ||| S:119 E:128 ||| FW
antigen  ||| S:128 E:136 ||| FW
receptor  ||| S:136 E:145 ||| FW
( ||| S:145 E:146 ||| -LRB-
CAR ||| S:146 E:149 ||| NNP
)  ||| S:149 E:151 ||| -RRB-
T  ||| S:151 E:153 ||| NN
cell  ||| S:153 E:158 ||| NN
therapies  ||| S:158 E:168 ||| NNS
hold  ||| S:168 E:173 ||| VBP
great  ||| S:173 E:179 ||| JJ
potential  ||| S:179 E:189 ||| NN
for  ||| S:189 E:193 ||| IN
treating  ||| S:193 E:202 ||| VBG
cancers ||| S:202 E:209 ||| NNS
,  ||| S:209 E:211 ||| ,
and  ||| S:211 E:215 ||| CC
new  ||| S:215 E:219 ||| JJ
CARs  ||| S:219 E:224 ||| NN
that  ||| S:224 E:229 ||| WDT
can  ||| S:229 E:233 ||| MD
target  ||| S:233 E:240 ||| VB
multiple  ||| S:240 E:249 ||| JJ
tumor  ||| S:249 E:255 ||| NN
types  ||| S:255 E:261 ||| NNS
and  ||| S:261 E:265 ||| CC
have  ||| S:265 E:270 ||| VB
the  ||| S:270 E:274 ||| DT
potential  ||| S:274 E:284 ||| JJ
to  ||| S:284 E:287 ||| TO
target  ||| S:287 E:294 ||| VB
non-hematological  ||| S:294 E:312 ||| JJ
malignancies  ||| S:312 E:325 ||| NNS
are  ||| S:325 E:329 ||| VBP
needed ||| S:329 E:335 ||| VBN
.  ||| S:335 E:337 ||| .
In  ||| S:337 E:340 ||| IN
this  ||| S:340 E:345 ||| DT
study ||| S:345 E:350 ||| NN
,  ||| S:350 E:352 ||| ,
the  ||| S:352 E:356 ||| DT
tumor  ||| S:356 E:362 ||| NN
recognition  ||| S:362 E:374 ||| NN
ability  ||| S:374 E:382 ||| NN
of  ||| S:382 E:385 ||| IN
a  ||| S:385 E:387 ||| DT
natural  ||| S:387 E:395 ||| JJ
killer  ||| S:395 E:402 ||| NN
cell-activating  ||| S:402 E:418 ||| JJ
receptor ||| S:418 E:426 ||| NN
,  ||| S:426 E:428 ||| ,
DNAM-1  ||| S:428 E:435 ||| NNP
was  ||| S:435 E:439 ||| VBD
harnessed  ||| S:439 E:449 ||| VBN
to  ||| S:449 E:452 ||| TO
design  ||| S:452 E:459 ||| VB
CARs  ||| S:459 E:464 ||| JJ
that  ||| S:464 E:469 ||| IN
target  ||| S:469 E:476 ||| NN
multiple  ||| S:476 E:485 ||| JJ
tumor  ||| S:485 E:491 ||| NN
types ||| S:491 E:496 ||| NNS
.  ||| S:496 E:498 ||| .
DNAM-1  ||| S:498 E:505 ||| NNP
ligands ||| S:505 E:512 ||| NN
,  ||| S:512 E:514 ||| ,
PVR  ||| S:514 E:518 ||| NNP
and  ||| S:518 E:522 ||| CC
nectin-2 ||| S:522 E:530 ||| NNP
,  ||| S:530 E:532 ||| ,
are  ||| S:532 E:536 ||| VBP
expressed  ||| S:536 E:546 ||| VBN
on  ||| S:546 E:549 ||| IN
primary  ||| S:549 E:557 ||| JJ
human  ||| S:557 E:563 ||| JJ
leukemia ||| S:563 E:571 ||| NN
,  ||| S:571 E:573 ||| ,
myeloma ||| S:573 E:580 ||| NN
,  ||| S:580 E:582 ||| ,
ovarian  ||| S:582 E:590 ||| JJ
cancer ||| S:590 E:596 ||| NN
,  ||| S:596 E:598 ||| ,
melanoma ||| S:598 E:606 ||| NN
,  ||| S:606 E:608 ||| ,
neuroblastoma ||| S:608 E:621 ||| NN
,  ||| S:621 E:623 ||| ,
and  ||| S:623 E:627 ||| CC
Ewing  ||| S:627 E:633 ||| NNP
sarcoma ||| S:633 E:640 ||| NN
.  ||| S:640 E:642 ||| .
DNAM-1  ||| S:642 E:649 ||| NNP
CARs  ||| S:649 E:654 ||| JJ
exhibit  ||| S:654 E:662 ||| NN
high  ||| S:662 E:667 ||| JJ
tumor  ||| S:667 E:673 ||| NN
cell  ||| S:673 E:678 ||| NN
cytotoxicity  ||| S:678 E:691 ||| NNS
but  ||| S:691 E:695 ||| CC
low  ||| S:695 E:699 ||| JJ
IFN-Î³  ||| S:699 E:705 ||| JJ
secretion  ||| S:705 E:715 ||| NN
in  ||| S:715 E:718 ||| IN
vitro ||| S:718 E:723 ||| NN
.  ||| S:723 E:725 ||| .
In  ||| S:725 E:728 ||| IN
contrast  ||| S:728 E:737 ||| NN
to  ||| S:737 E:740 ||| TO
other  ||| S:740 E:746 ||| JJ
CAR  ||| S:746 E:750 ||| NN
designs ||| S:750 E:757 ||| NNS
,  ||| S:757 E:759 ||| ,
co-stimulatory  ||| S:759 E:774 ||| JJ
domains  ||| S:774 E:782 ||| NN
did  ||| S:782 E:786 ||| VBD
not  ||| S:786 E:790 ||| RB
improve  ||| S:790 E:798 ||| VB
the  ||| S:798 E:802 ||| DT
expression  ||| S:802 E:813 ||| NN
and  ||| S:813 E:817 ||| CC
function  ||| S:817 E:826 ||| NN
of  ||| S:826 E:829 ||| IN
DNAM-1  ||| S:829 E:836 ||| NNP
CARs ||| S:836 E:840 ||| NNP
.  ||| S:840 E:842 ||| .
A  ||| S:842 E:844 ||| DT
DNAM-1 ||| S:844 E:850 ||| NNP
/ ||| S:850 E:851 ||| NNP
CD3zeta  ||| S:851 E:859 ||| NNP
CAR  ||| S:859 E:863 ||| NNP
reduced  ||| S:863 E:871 ||| VBD
tumor  ||| S:871 E:877 ||| JJ
burden  ||| S:877 E:884 ||| NN
in  ||| S:884 E:887 ||| IN
a  ||| S:887 E:889 ||| DT
murine  ||| S:889 E:896 ||| JJ
melanoma  ||| S:896 E:905 ||| JJ
model  ||| S:905 E:911 ||| NN
in  ||| S:911 E:914 ||| IN
vivo ||| S:914 E:918 ||| NN
.  ||| S:918 E:920 ||| .
In  ||| S:920 E:923 ||| IN
conclusion ||| S:923 E:933 ||| NN
,  ||| S:933 E:935 ||| ,
DNAM-1-based  ||| S:935 E:948 ||| NNP
CARs  ||| S:948 E:953 ||| NNP
may  ||| S:953 E:957 ||| MD
have  ||| S:957 E:962 ||| VB
the  ||| S:962 E:966 ||| DT
potential  ||| S:966 E:976 ||| JJ
to  ||| S:976 E:979 ||| TO
treat  ||| S:979 E:985 ||| VB
PVR  ||| S:985 E:989 ||| NNP
and  ||| S:989 E:993 ||| CC
nectin-2  ||| S:993 E:1002 ||| CD
expressing  ||| S:1002 E:1013 ||| CD
hematological  ||| S:1013 E:1027 ||| NNS
and  ||| S:1027 E:1031 ||| CC
solid  ||| S:1031 E:1037 ||| JJ
tumors ||| S:1037 E:1043 ||| NNS
.  ||| S:1043 E:1045 ||| .
